Davita (NYSE:DVA)‘s stock had its “hold” rating reiterated by analysts at SunTrust Banks in a note issued to investors on Wednesday. They currently have a $80.00 price objective on the stock. SunTrust Banks’ price target would suggest a potential upside of 7.02% from the company’s previous close.
A number of other research firms also recently commented on DVA. JPMorgan Chase & Co. boosted their price objective on shares of Davita from $4.90 to $84.00 and gave the stock a “strong-buy” rating in a report on Thursday, December 7th. Citigroup raised shares of Davita from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $67.71 to $82.00 in a report on Monday, December 11th. Robert W. Baird reissued a “hold” rating and set a $63.00 price objective on shares of Davita in a report on Friday, November 10th. Raymond James Financial raised shares of Davita from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $65.00 to $84.00 in a report on Thursday, December 7th. Finally, Bank of America decreased their price objective on shares of Davita from $75.00 to $66.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $79.30.
Shares of Davita (NYSE DVA) traded up $1.21 during trading on Wednesday, hitting $74.75. 2,581,726 shares of the stock were exchanged, compared to its average volume of 1,472,765. Davita has a twelve month low of $52.51 and a twelve month high of $80.71. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. The firm has a market capitalization of $13,456.05, a price-to-earnings ratio of 28.70 and a beta of 0.99.
In other Davita news, insider Charles Berg sold 7,048 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $69.24, for a total value of $488,003.52. Following the sale, the insider now owns 5,359 shares of the company’s stock, valued at $371,057.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James K. Hilger sold 5,608 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $69.46, for a total transaction of $389,531.68. Following the completion of the sale, the insider now directly owns 47,649 shares in the company, valued at approximately $3,309,699.54. The disclosure for this sale can be found here. Insiders sold 121,509 shares of company stock worth $8,310,388 in the last ninety days. Insiders own 2.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Davita in the third quarter valued at about $154,000. IFG Advisory LLC acquired a new position in shares of Davita in the fourth quarter valued at approximately $205,000. Country Club Trust Company n.a. acquired a new position in shares of Davita in the fourth quarter valued at approximately $207,000. Berkshire Asset Management LLC PA acquired a new position in shares of Davita in the fourth quarter valued at approximately $234,000. Finally, Ferguson Wellman Capital Management Inc. acquired a new position in shares of Davita in the fourth quarter valued at approximately $236,000. 84.45% of the stock is currently owned by institutional investors.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.